Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

and both trials were placed on clinical hold by the U.S. Food and Drug Administration in February 2024 due to a serious adverse event of liver injury requiring transplant in one patient in the AD ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

Uber’s mobility revenue rose 26%, boosting Q3 results. Comcast saw Peacock subscribers surge from Olympics; Peloton and Merck ...

Gardasil, which prevents cancers caused by the human papillomavirus, has been one of Merck's top growth drivers aside from blockbuster cancer treatment Keytruda, and much of its international growth ...

"Paris seemed to represent a renaissance as far as Olympics go with strong viewership, effective utilization of Peacock in a ...

When Wiley Harp discovered blood in his urine on September 20, 2023, he knew something was wrong. An X-ray at Baptist-St.

V940 is an investigational individualized neoantigen therapy under development in combination with Keytruda (pembrolizumab) as adjuvant treatment for resectable Stage II, IIIA or IIIB (N2 ...